Theravance Biopharma TBPH Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's total equity?
- Theravance Biopharma (TBPH) reported total equity of $290.59M in Q1 2026.
- How has Theravance Biopharma's total equity changed year-over-year?
- Theravance Biopharma's total equity increased by 75.1% year-over-year, from $165.98M to $290.59M.
- What is the long-term trend for Theravance Biopharma's total equity?
- Over 5 years (2020 to 2025), Theravance Biopharma's total equity has grown at a -0.5% compound annual growth rate (CAGR), from -$303.75M to $296.72M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.